What is Novocure's gross profit margin?

Did Novocure beat or miss consensus estimates last quarter?

What is Novocure's latest dividend and current dividend yield?

What were the key takeaways from Novocure's earnings call?

What were the key takeaways from Novocure’s earnings call?

What is the revenue and EPS growth rate for Novocure year over year?

What does Novocure do and what are its main business segments?

What guidance did Novocure's management provide for the next earnings period?

- **FDA Approval Milestone**: Optune Pax for pancreatic cancer approved 3 months ahead of schedule.
- **2026 Growth Path**: $675-705M revenue target (+3-8%), driven by GBM ex-US expansion and new indications.
- **Profitability Focus**: 2026 adj. EBITDA guidance of -20M to breakeven reflects cost discipline.
- **Key Risk**: 1-2 year payer coverage timeline for Optune Pax may delay revenue realization.

**【Executive Chairman's Remarks】**
- **2025 Highlights**: Record $655M net revenue (8% YoY growth), FDA approval of Optune Pax for pancreatic cancer, and PMA submissions for brain metastases. 
- **2026 Catalysts**: Optune Pax launches in U.S. and Germany, TRIDENT Phase III GBM trial readout, and Optune Lua launch in Japan.
- **Organizational Change**: CMO resignation; Chief Innovation Officer Uri Weinberg now dual-role CMO & CCO to accelerate R&D.

**【CEO Commercial Update】**
- **GBM Growth**: 19% YoY in France, 29% in Japan; U.S. growth 4% after years of stagnation.
- **Optune Pax Launch**: FDA approval in 180 days vs. 9-12 month industry norm; leveraging existing torso sales force for pancreatic oncologists.
- **Market Strategy**: Prioritizing high-potential markets (Spain, Czechia) over slower Optune Lua launches in U.S. & Germany.

**【CFO Financial Review】**
- **Q4 2025 Results**: $174M net revenue, $24M net loss, $16M adj. EBITDA loss.
- **2026 Guidance**: $675-705M net revenue (3-8% growth), adj. EBITDA -20M to breakeven.
- **Key Metrics**: Gross margin ~76% (mid-70s% in 2026), R&D spend $225M in 2025, $5M FX tailwind.

**【Q&A Highlights】**
- **Optune Pax TAM**: 15,000 U.S. patients/year; expects 1-2 years to secure payer coverage.
- **Sales Force Utilization**: No new hires; repurposing existing torso team for pancreatic oncology.
- **Revenue Lag**: 6-12 month delay between patient starts and revenue due to payer appeals process.
- **Guidance Assumptions**: 3% GBM growth, $15-25M new indication contributions (Optune Pax, Lua).

NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 net revenue $167M (+8% YoY), driven by GBM patient expansion (4,277 active patients).
- **Lung Cancer Struggles**: 100 patients on therapy (94 in U.S.), facing headwinds from drug competition and device complexity. Japan launch expected to accelerate growth.
- **Upcoming Launches**: Pancreatic cancer and brain metastases FDA approvals anticipated in 2026, leveraging existing infrastructure.
- **Financial Targets**: Adjusted EBITDA breakeven in 2027 at $700-750M revenue, supported by disciplined expense management.
- **Product Innovation**: 78% U.S. GBM patients using new app, HFE array global rollout complete, and MAXPOINT software FDA submission.

**【Management Opening Remarks】**
- **Mission Expansion**: Transitioning from a single-indication to a platform therapy company, targeting 4 cancer indications by end-2026 (GBM, lung, pancreatic, brain metastases).
- **Priorities**: Launch new indications, achieve profitability, and invest in product portfolio.
- **Q3 Highlights**: 4,277 active GBM patients (5% YoY growth), 100 lung cancer patients (94 in U.S.), and regulatory approvals for Japan lung cancer launch.

**【CEO Commentary】**
- **Regulatory Progress**: FDA submissions for pancreatic cancer (PANOVA-3) and brain metastases (METIS) expected in 2026. Japan filings for pancreatic and lung cancer underway.
- **Product Development**: Rollout of HFE arrays globally, new patient app adoption (78% U.S. GBM patients), and MAXPOINT treatment planning software FDA submission.
- **Clinical Trials**: PANOVA-4 (metastatic pancreatic cancer) data expected Q1 2026, TRIDENT (GBM concurrent TTFields + radiation) Q2 2026.

**【CFO Financial Commentary】**
- **Q3 Financials**: Net revenue $167M (+8% YoY), gross margin 73%, adjusted EBITDA -$3M (vs. -$12M YoY improvement).
- **Expense Management**: R&D $54M (4% YoY), SG&A $46M (15% YoY), driven by share-based compensation and infrastructure build.
- **Cash Position**: $1.03B, with $561M convertible notes redeemed. Targeting adjusted EBITDA breakeven in 2027 at $700-750M revenue run rate.

**【Q&A Highlights】**
- **Lung Cancer Challenges**: Slow adoption due to physician preference for drugs, device complexity, and patient health. Japan launch expected to outperform U.S. due to reimbursement structure and physician familiarity with devices.
- **Gross Margin Trajectory**: 73% Q3, mid-70s for 2025, recovery to high-70s post-launches as reimbursement catches up to patient growth.
- **Pancreatic Launch Strategy**: Leverage existing GBM infrastructure, focus on high-burden regions, and use real-world evidence to support trials.


NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript

- **Clinical Milestones**: PANOVA-3 trial shows 3-month OS benefit in pancreatic cancer; METIS trial demonstrates 28% risk reduction in brain metastases progression.
- **Commercial Momentum**: 121 NSCLC prescriptions in Q2, $1.1M U.S. collections, and 7% YoY active patient growth in GBM.
- **Financial Health**: $912M cash balance to support 2026 launches; targeting $750M revenue for adjusted EBITDA breakeven.
- **Regulatory Progress**: PANOVA-3 PMA submission expected Q3 2025; METIS PMA on track for late 2025.

**【Management Opening Remarks】**
- Ingrid Goldberg provided an overview of the call, emphasizing the importance of non-GAAP metrics like adjusted EBITDA and the availability of slides for reference.

**【CEO Summary Section】**
- **Pancreatic Cancer Progress**: Presented PANOVA-3 trial results showing a 2-month overall survival (OS) improvement in the intent-to-treat population and 3 months in the modified ITT group. TTFields also extended pain-free survival by 6 months.
- **Brain Metastases Update**: METIS trial met primary endpoint with a 28% risk reduction in time to intracranial progression (TTP) vs. supportive care alone (15 vs. 7.5 months). FDA PMA submission for NSCLC brain mets is on track for late 2025.
- **Upcoming Data**: PANOVA-4 (pancreatic + immunotherapy) and Driving (GBM concurrent chemoradiation) trials are fully enrolled, with readouts expected in H1 2026.
- **FDA Filings**: PANOVA-3 PMA submission expected Q3 2025, with METIS submission following. Both anticipate 9-12 month reviews post-acceptance.

**【CEO Commercial Update】**
- **Optune Lua Launch**: 121 NSCLC prescriptions (106 U.S., 15 Germany) in Q2, 137 active patients globally. U.S. collections reached $1.1M, with 93% of ICI-treated patients having prior ICI exposure.
- **GBM Growth**: 4,194 active patients (+7% YoY), driven by double-digit growth in ex-U.S. markets. Mayo Clinic real-world study showed 58% 2-year survival with TTFields vs. 41% without.

**【CFO Financial Commentary】**
- **Revenue**: $159M net revenue (+6% YoY), driven by 7% active patient growth. NSCLC collections totaled $2.4M (including $1.1M U.S.).
- **Gross Margin**: 74% (vs. 77% Q2 2024), impacted by HF rate rollout and NSCLC launch costs.
- **Expenses**: R&D $56M (+2%), SG&A $101M (+17%) due to launch expenses and E&IT investments. Net loss $40M, adjusted EBITDA -$10M.
- **Cash Position**: $912M, with plans to retire $560M convertible notes using balance sheet cash.

**【Q&A Highlights】**
- **Optune Lua Ramp**: Q2 NSCLC prescriptions grew 14% QoQ, slower than expected. Company attributes this to physician education needs but remains confident in 2025 $5-10M collection target.
- **METIS Data Consistency**: Final cleaned dataset confirmed statistical significance (p=0.044) vs. initial ASCO presentation.
- **Regulatory Path**: PANOVA-3 PMA submission will leverage existing GBM approval for faster review. NSCLC launch in Japan expected within months.
- **Profitability Path**: Targeting $750M revenue threshold for adjusted EBITDA breakeven, with gradual margin improvement as NSCLC reimbursement expands.

NovoCure Limited (NVCR)-24 Jul 25-2025 Q2 Earnings call transcript

- **NSCLC Launch Accelerating**: 92 prescriptions and 62 active patients in Q1, with 60% new prescribers and 50-50 split between ICI and docetaxel use.
- **GBM Growth Strong**: Record 4,162 global active patients, +46% YoY in France and +17% in Japan.
- **PANOVA-3 ASCO Debut**: First Phase 3 trial to show OS benefit in locally advanced pancreatic cancer; data to be presented at ASCO.
- **Financial Resilience**: $155M revenue (+12% YoY) despite 75% gross margin; $929M cash balance supports multi-indication expansion.
- **Risks and Mitigation**: Tariffs could impact COGS by $8-11M, but cost reductions and linear launch strategy maintain financial discipline.

**【Management Opening Remarks】**
- **Mission and Milestones**: CEO Bill Doyle highlighted 2025 as a pivotal year for Novocure, transitioning from a single-indication GBM company to a multi-indication oncology leader. Key achievements include CE Mark approval for Optune Lua in metastatic NSCLC (Europe) and acceptance of PANOVA-3 data for ASCO presentation.
- **Upcoming Events**: Investor event on May 31 to discuss PANOVA-3 results; regulatory review ongoing in Japan for NSCLC launch later this year.

**【CEO Ashley Cordova’s Q1 Update】**
- **NSCLC Launch Momentum**: 92 prescriptions and 62 active patients in Q1, with 60% of prescribers new to tumor treating fields (TTF). 50-50 split between concomitant ICI and docetaxel use, aligning with real-world treatment patterns.
- **GBM Growth**: Record 4,162 global active patients, driven by 46% YoY growth in France and 17% in Japan. HFE array rollout and patient app adoption (1,400 users in the U.S.) enhance patient engagement.
- **Pipeline Progress**: PMA submissions for METIS (mesothelioma) and PANOVA-3 (pancreatic cancer) on track for 2025. Phase 3 trials (TRIDENT, LUNAR-2) fully enrolled; Phase 2 LUNAR-4 enrolling patients.

**【CFO Christoph Brackmann’s Financial Review】**
- **Revenue Performance**: $155M net revenue (+12% YoY), driven by 11% active patient growth. NSCLC revenue reflects cash collections due to early launch phase.
- **Gross Margin Challenges**: 75% gross margin (-1% YoY) due to HFE array costs and NSCLC launch. Tariffs could impact 2025 COGS by $8-11M, but cost reductions offset部分影响.
- **Expense Management**: R&D ($54M), S&M ($56M), and G&A ($45M) stable, with focus on leveraging infrastructure for multi-indication growth. Net loss of $34M; $929M cash balance supports future launches.

**【Q&A Highlights】**
- **NSCLC vs GBM Launch**: Linear growth strategy prioritizes right physician, patient, and timing. 93 unique prescribers (60% new to TTF) suggest strong adoption potential. Q1 scripts (~25% of GBM launch pace) reflect early-stage focus on second/third-line use.
- **PANOVA-3 Expectations**: ASCO presentation will include full OS curves, secondary endpoints (response rates, surgical operability). Trial design (Gem Abraxane control arm) validated by 2-month OS benefit in locally advanced pancreatic cancer.
- **Reimbursement Strategy**: Germany launch follows U.S. case-by-case model, with early focus on high-likelihood reimbursement cases. U.S. NSCLC collections exceed expectations, supporting revenue recognition as track record builds.
- **Tariff Mitigation**: Supply chain optimizations offset tariff risks; gross margin expected to remain in low 70s for 2025.


NovoCure Limited (NVCR)-24 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Expansion**: 2024 revenue up 19% to $605M, driven by GBM growth and U.S. approvals. 
- **Lung Cancer Breakthrough**: 52 prescriptions in first 2 months post-FDA approval, targeting 2026 coverage expansion. 
- **Pipeline Potential**: METIS and PANOVA-3 trials demonstrate survival benefits, targeting 7x GBM patient population. 
- **Financial Strength**: $960M cash on hand, with 2025 focused on scaling for multi-indication growth. 


**【CEO Summary Section】**
- **Revenue Growth**: Achieved $605 million in 2024, up 19% YoY, driven by GBM patient growth (+10% to 4,000+ active patients) and improved U.S. approval rates. 
- **Lung Cancer Launch**: Received FDA approval for Optune Lua in Q4 2024, with 52 prescriptions and 20 active patients by year-end. Payer coverage expected to expand in 2026. 
- **Pipeline Success**: METIS (brain mets) and PANOVA-3 (pancreatic cancer) trials met primary endpoints, with potential 7x GBM TAM expansion. 
- **Product Innovation**: Launched HFE arrays (thinner, lighter) globally, improving patient adherence and market access. 

**【CFO Financial Commentary】**
- **Q4 2024 Results**: $161 million revenue (+21% YoY), $605 million annual revenue (+19% YoY). U.S. prior-period claims contributed $22.3 million. 
- **Gross Margin**: 77% annual (vs. 75% 2023), driven by U.S. pricing. 2025 headwinds from HFE arrays and lung launch expected to lower margin to low 70s. 
- **Expenses**: S&M $239 million (+5%), R&D $210 million (-6%). 2025 focus on GBM stability and lung demand generation. 
- **Cash Position**: $960 million as of Q4, sufficient to meet $561 million convertible note maturity. 

**【Q&A Key Themes】**
- **Lung Launch Momentum**: 52 prescriptions in Q4, 20 active patients. Payer discussions progressing, with coverage expected in 2026. 
- **Pipeline Progress**: METIS and PANOVA-3 data to be published in 2025, with FDA pre-submission discussions underway. 
- **China Dynamics**: Q4 decline due to royalty amortization roll-off; 2025 outlook stable with GBM as foundation. 
- **Financial Outlook**: 2025 focused on demand generation; 2026+ revenue growth from lung, brain mets, and pancreatic cancer launches. 


Actual											0.04	0.02	0.09	0.04	-0.04	-0.14	-0.13	-0.25	-0.04	-0.23	-0.25	-0.36	-0.5	-0.54	-0.46	-0.45	-0.36	-0.31	-0.28	-0.61	-0.31	-0.36	-0.33	-0.22
Forecast											0.0343	-0.0038	0.0389	0.1256	0.015	0.0088	-0.0738	-0.1025	-0.185	-0.145	-0.2614	-0.3025	-0.3229	-0.5	-0.525	-0.5214	-0.42	-0.4029	-0.3338	-0.3443	-0.4641	-0.3841	-0.4197	-0.4114
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+16.62%	+626.32%	+131.36%	-68.15%	-366.67%	-1690.91%	-76.15%	-143.90%	+78.38%	-58.62%	+4.36%	-19.01%	-54.85%	-8.00%	+12.38%	+13.69%	+14.29%	+23.06%	+16.12%	-77.17%	+33.20%	+6.27%	+21.37%	+46.52%

NVCR

NVCR fundamentals

NVCR Q4 2025 Earnings

Earnings Call

You can ask Aime

NVCR

NVCR fundamentals

NVCR Q4 2025 Earnings

Earnings Call

NVCR Earnings Call Summary for Q4/20258:00 AM on Feb 26, 2026

NVCR Earnings Call Summary for Q3/20258:00 AM on Oct 30, 2025

NVCR Earnings Call Summary for Q2/20258:00 AM on Jul 24, 2025

NVCR Earnings Call Summary for Q1/20258:00 AM on Apr 24, 2025

NVCR Earnings Call Summary for Q4/20248:00 AM on Feb 27, 2025

You can ask Aime